Full Press Release Details
ALAMEDA, Calif. , Aug. 1, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023 .
• Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency 1 compared to the second quarter of 2022.
Second Quarter 2023 Financial Results Total revenue increased to $261.5 million for the second quarter of 2023 compared to $208.3 million for the second quarter of 2022, an increase of 25.5% as reported and on a constant currency basis. The United States represented 71% of total revenue and international represented 29% of total revenue for the second quarter of 2023. Revenue from sales of vascular products grew to $152.7 million for the second quarter of 2023, an increase of 23.6%, or 23.7% on a constant currency basis. Revenue from sales of neuro products grew to $108.8 million for the second quarter of 2023, an increase of 28.3%, or 28.1% on a constant currency basis.
Gross profit was $166 .9 million, or 63.8% of total revenue for the second quarter of 2023, compared to $134 .0 million, or 64.3% of total revenue, for the second quarter of 2022. Gross margin is impacted by product mix, regional mix, start-up costs associated with new product launches, and macroeconomic factors such as inflation headwinds. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.
Total operating expenses were $149.0 million , or 57.0% of total revenue, for the second quarter of 2023, including a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. This compares to total operating expenses of $134.2 million , or 64.4% of total revenue, for the second quarter of 2022, including a $1.8 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding this charge, total non-GAAP operating expenses 1 were $146.6 million , or 56.1% of total revenue, for the second quarter of 2023, and $132.4 million , or 63.5% of total revenue, for the second quarter of 2022, respectively. R&D expenses were $21.5 million for the second quarter of 2023, compared to $19.6 million for the second quarter of 2022. SG&A expenses were $127 .4 million for the second quarter of 2023, compared to $114 .6 million for the second quarter of 2022.
Income from operations was $17 .9 million for the second quarter of 2023, compared to a loss from operations of $0 .1 million for the second quarter of 2022. Excluding the charge associated with the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, non-GAAP income from operations 1 was $20 .3 million for the second quarter of 2023, compared to non-GAAP income from operations 1 of $1 .6 million for the second quarter of 2022.
Updated Full Year 2023 Financial Outlook The Company is increasing its guidance for 2023 total revenue to be in the range of $1.05 billion to $1.07 billion , which represents 24% to 26% growth over 2022 revenue of $847.1 million . We continue to expect growth in our global vascular business to be slightly above this range and growth in our global neuro business to be below this range for the full year 2023.
Webcast and Conference Call Information Penumbra, Inc. will host a conference call to discuss the second quarter 2023 financial results after market close on Tuesday, August 1, 2023 at 4:30 PM Eastern Time . The conference call can be accessed live over the phone by dialing (888) 330-2443 for domestic and international callers (conference id: 4604622), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com . The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra Penumbra, Inc., headquartered in Alameda, California , is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn .
1 See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.
Non-GAAP Financial Measures In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency and b) non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income and non-GAAP diluted earnings per share ("EPS").
Constant Currency . The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
Non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
• the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives; and
• the excess tax benefits or tax deficiencies associated with share-based compensation arrangements.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition and the excess tax benefits or tax deficiencies associated with share-based compensation arrangements.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
June 30, 2023
December 31, 2022
Assets
Current assets:
Cash and cash equivalents
$ 114,167
$ 69,858
Marketable investments
106,896
118,172
Accounts receivable, net
208,965
203,384
Inventories
358,770
334,006
Prepaid expenses and other current assets
39,078
30,279
Total current assets
827,876
755,699
Property and equipment, net
65,958
65,015
Operating lease right-of-use assets
187,494
192,636
Finance lease right-of-use assets
31,751
33,323
Intangible assets, net
76,116
81,161
Goodwill
166,166
166,046
Deferred taxes
66,671
64,213
Other non-current assets
10,500
12,793
Total assets
$ 1,432,532
$ 1,370,886
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$ 25,819
$ 26,679
Accrued liabilities
105,606
106,300
Current operating lease liabilities
10,715
10,033
Current finance lease liabilities
1,984
1,920
Total current liabilities
144,124
144,932
Non-current operating lease liabilities
194,655
198,955
Non-current finance lease liabilities
23,922
24,865
Other non-current liabilities
3,288
3,276
Total liabilities
365,989
372,028
Stockholders' equity:
Common stock
38
38
Additional paid-in capital
1,000,658
963,040
Accumulated other comprehensive loss
(5,579)
(8,124)
Retained earnings
71,426
43,904
Total stockholders' equity
1,066,543
998,858
Total liabilities and stockholders' equity
$ 1,432,532
$ 1,370,886
Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2023
2022
2023
2022
Revenue
$ 261,499
$ 208,344
$ 502,897
$ 412,239
Cost of revenue
94,638
74,309
184,964
150,786
Gross profit
166,861
134,035
317,933
261,453
Operating expenses:
Research and development
21,537
19,559
41,523
40,123
Sales, general and administrative
127,435
114,615
250,513
225,515
Total operating expenses
148,972
134,174
292,036
265,638
Income (loss) from operations
17,889
(139)
25,897
(4,185)
Interest income (expense), net
839
(72)
1,393
(119)
Other income (expense), net
808
(956)
898
(1,967)
Income (loss) before income taxes
19,536
(1,167)
28,188
(6,271)
Provision for (benefit from) income taxes
576
2,520
666
(2,663)
Net income (loss)
$ 18,960
$ (3,687)
$ 27,522
$ (3,608)
Net income (loss) per share:
Basic
$ 0.49
$ (0.10)
$ 0.72
$ (0.10)
Diluted
$ 0.48
$ (0.10)
$ 0.70
$ (0.10)
Weighted average shares outstanding:
Basic
38,320,999
37,767,519
38,254,042
37,707,156
Diluted
39,201,155
37,767,519
39,151,412
37,707,156
Penumbra, Inc.
Reconciliation of GAAP Operating Expenses and GAAP Income (Loss) from Operations to Non-GAAP Operating Expenses
and Non-GAAP Income (Loss) from Operations 1
(unaudited)
(in thousands)
Three Months Ended June 30,
Six Months Ended June 30,
2023
2022
2023
2022
GAAP operating expenses
$ 148,972
$ 134,174
$ 292,036
$ 265,638
GAAP operating expenses includes the effect of the following item:
Amortization of finite lived intangible assets acquired
2,380
1,785
4,759
3,569
Non-GAAP operating expenses
$ 146,592
$ 132,389
$ 287,277
$ 262,069
GAAP income (loss) from operations
$ 17,889
$ (139)
$ 25,897
$ (4,185)
GAAP income (loss) from operations includes the effect of the following item:
Amortization of finite lived intangible assets acquired
2,380
1,785
4,759
3,569
Non-GAAP income (loss) from operations
$ 20,269
$ 1,646
$ 30,656
$ (616)
1 See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.
Penumbra, Inc.
Reconciliation of GAAP Net Income (Loss) and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS 1
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended
June 30, 2023
Three Months Ended
June 30, 2022
Six Months Ended
June 30, 2023
Six Months Ended
June 30, 2022
Net
income
Diluted
EPS
Net (loss)
income
Diluted
EPS
Net
income
Diluted
EPS
Net (loss)
income
Diluted
EPS
GAAP net income (loss)
$ 18,960
$ 0.48
$ (3,687)
$ (0.10)
$ 27,522
$ 0.70
$ (3,608)
$ (0.10)
GAAP net income (loss) includes the effect of the
following items:
Amortization of finite lived intangible assets acquired
2,380
0.06
1,785
0.05
4,759
0.13
3,569
0.10
Tax effect on the non-GAAP adjustment above 2
(558)
(0.01)
(416)
(0.01)
(1,116)
(0.03)
(832)
(0.02)
(Excess tax benefits) tax deficiencies related to stock
compensation awards
(3,945)
(0.10)
2,725
0.07
(5,385)
(0.14)
944
0.02
Non-GAAP net income
$ 16,837
$ 0.43
$ 407
$ 0.01
$ 25,780
$ 0.66
$ 73
$ 0.00
Weighted average shares outstanding used to compute:
GAAP diluted EPS
39,201,155
37,767,519
39,151,412
37,707,156
Non-GAAP diluted EPS 3
39,201,155
38,686,507
39,151,412
38,722,453
1 See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.
2 For the three and six months ended June 30, 2023 and 2022, management used a combined federal and state tax rate of 23.44% and 23.29%, respectively, to compute the tax effect of non-GAAP adjustments.
3 For the purposes of calculating Non-GAAP diluted EPS for the three and six months ended June 30, 2022, non-GAAP diluted weighted average shares outstanding of 38,686,507 and 38,722,453 respectively were used, as the Company had non-GAAP net income in the period.
Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth 1
(unaudited)
(in thousands, except for percentages)
Three Months Ended June 30,
Reported Change
FX Impact
Constant Currency Change
2023
2022
$
%
$
$
%
United States
$ 186,772
$ 141,456
$ 45,316
32.0 %
$ —
$ 45,316
32.0 %
International
74,727
66,888
7,839
11.7 %
(84)
7,755
11.6 %
Total
$ 261,499
$ 208,344
$ 53,155
25.5 %
$ (84)
$ 53,071
25.5 %
Six Months Ended June 30,
Reported Change
FX Impact
Constant Currency Change
2023
2022
$
%
$
$
%
United States
$ 358,651
$ 285,764
$ 72,887
25.5 %
$ —
$ 72,887
25.5 %
International
144,246
126,475
17,771
14.1 %
2,418
20,189
16.0 %
Total
$ 502,897
$ 412,239
$ 90,658
22.0 %
$ 2,418
$ 93,076
22.6 %
Penumbra, Inc.
Reconciliation of Revenue Growth by Product Categories to Constant Currency Revenue Growth 1
(unaudited)
(in thousands, except for percentages)
Three Months Ended June 30,
Reported Change
FX Impact
Constant Currency Change
2023
2022
$
%
$
$
%
Vascular
$ 152,684
$ 123,543
$ 29,141
23.6 %
$ 111
$ 29,252
23.7 %
Neuro
108,815
84,801
24,014
28.3 %
(195)
23,819
28.1 %
Total
$ 261,499
$ 208,344
$ 53,155
25.5 %
$ (84)
$ 53,071
25.5 %
Six Months Ended June 30,
Reported Change
FX Impact
Constant Currency Change
2023
2022
$
%
$
$
%
Vascular
$ 295,533
$ 246,352
$ 49,181
20.0 %
$ 1,118
$ 50,299
20.4 %
Neuro
207,364
165,887
41,477
25.0 %
1,300
42,777
25.8 %
Total
$ 502,897
$ 412,239
$ 90,658
22.0 %
$ 2,418
$ 93,076
22.6 %
1 See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.